Durban – JSE-listed Aspen Pharmacare Holdings Limited (“Aspen”) today announced the successful completion of the divestment of its Asia Pacific (“APAC”) business comprising Australia, New Zealand and other Asia Pacific regions (excluding China), marking a significant milestone in the Group’s strategic journey.
The transaction was concluded for a consideration of AUD 2,37 billion, generating aggregate net proceeds of approximately R27 billion, strengthening Aspen’s balance sheet and providing enhanced financial flexibility.
Aspen Group Chief Executive, Stephen Saad, said “This transaction represents a compelling outcome for Aspen and it is a significant milestone in our ongoing strategy to unlock and realise value for shareholders. Importantly, it demonstrates the inherent value that has been created within Aspen over time.”
The APAC business, originally established as a relatively modest start-up with limited resources, has evolved into a meaningful contributor to Aspen’s earnings, cash flows, and overall market capitalisation.
Saad added, “The APAC portfolio is a testament to Aspen’s ability to build, scale and enhance businesses. From its early beginnings, the business segment has grown into a leading pharmaceutical business in the region making a sustainable and meaningful financial contribution to the Group. The realisation of this value through the transaction underscores the strength of Aspen’s operating model.”
He said that Aspen is deeply appreciative of all those who contributed to the success of the APAC business and the completion of the transaction. “We extend our sincere thanks to all stakeholders involved in bringing this transaction to fruition. Most importantly, we recognise and thank the management team and employees of the APAC business for their dedication, professionalism and contribution to Aspen over many years.”
Looking ahead, Stephen expressed the Group’s support for the business under its new ownership. “As the APAC business embarks on its next chapter under new ownership, we wish the company, its management team and all employees continued success. We are confident that the strong foundation built over the years will support future growth and prosperity.”
Transaction Overview and Proceeds
· The Transaction Consideration remained unchanged at AUD 2,370 million with no adjustments at the Completion Date.
· Transaction and other related costs incurred amounted to less than 5% of the Transaction Consideration, consistent with guidance provided in the Circular distributed to Shareholders on Thursday 19 March 2026. (the “Circular”).
· Aggregate net proceeds are estimated to be approximately R27 billion, (compared to the c.R25 billion estimate included in the Circular).
· Net proceeds have been applied primarily toward the reduction of Group debt, consistent with the strategy outlined in the Circular.
· The Group’s balance sheet has been materially strengthened, underpinned by enhanced flexibility, positioning it to pursue potential capital allocation opportunities.
The Transaction Consideration received for the APAC divestment represents a compelling value and provides a tangible demonstration of the value created within the Group over time. Consistent with the Group’s strategy to further unlock the underlying sum-of-the-parts value, the Board is of the view that the current share price does not fully reflect the intrinsic value of Aspen’s underlying businesses and growth prospects, particularly in light of both the improved balance sheet position and future earnings profile of the continuing operations. The enhanced balance sheet flexibility also provides greater scope to consider share buybacks as a means of delivering returns to Shareholders.